Navigation Links
Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
Date:4/9/2008

Phase III study will evaluate effects of otelixizumab, an investigational

anti-CD3 monoclonal antibody, on preservation of endogenous insulin

secretion

CAMBRIDGE, Mass., April 9, 2008 /PRNewswire/ - Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced that it is proceeding toward the initiation of a Phase III study of otelixizumab in new-onset type 1 diabetes. Tolerx is initiating this pivotal trial after reviewing the results of the otelixizumab development program with the US Food and Drug Administration (FDA) at an End of Phase II meeting.

The Phase III study, known as DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), will be conducted at multiple centers in North America and Europe and will evaluate whether a single course of otelixizumab reduces the amount of administered insulin required for control of blood glucose levels by inhibiting destruction of beta cells. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events and reduction of long term disease complications in established diabetics in the Diabetes Control and Complications Trial (DCCT). DEFEND enrollment is expected to begin mid-2008.

"We are very pleased with the outcome of the End of Phase II meeting with FDA and the opportunity to advance initiation of the DEFEND trial. This step is a significant and important milestone for Tolerx," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "The rigorous science behind our Phase II clinical program has provided us with valuable insights that facilitated our moving forward into DEFEND with an optimized dosing regimen that has the potential to transform the treatment paradigm for type 1 diabetes."

"We have worked closely with FDA over several years to ensure that
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Novel Technology Breaks Through Cancer Pain
3. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
8. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
9. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
10. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , July 4, 2015 ... for patients with unresectable metastatic colorectal cancer in ... that organ Patients with unresectable metastatic ... the liver experienced the greatest improvement in Progression-Free ... of SIR-Spheres Y-90 resin microspheres to a current ...
(Date:7/3/2015)... HUATULCO, Mexico , July 3, 2015 ... targeting the epidemics of hypertension, diabetes and thyroid disorders ... online educational platforms and a major conference dedicated to ... Manage Diabetes Online , Manage Hypertension ... each developed and operated by EXCEMED - ...
(Date:7/2/2015)... 3 juillet 2015 BGI a annoncé aujourd,hui ... de l,ADN situé à Hong Kong ... College of Pathologists  (Collège des pathologistes américains, ou ... Hong Kong constituent le premier laboratoire ... la certification du CAP en Chine, car il ...
Breaking Medicine Technology:New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2
... 23 Neurobiological Technologies, Inc. (Nasdaq: NTII ) ("NTI") ... extraordinary dividend of $0.18 per share of common stock, which ... record as of November 30, 2009. The December 9, 2009 ... pursuant to a plan of complete liquidation and dissolution and ...
... Calif., Nov. 23 Advanced Sterilization Products (ASP), ... today the acquisition by its French affiliate, Apsis ... of innovative disinfection processes and technologies to prevent ... disclosed. , Gloster Europe designs and markets ...
Cached Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new ... a buzz of media attention. In an effort to spread the news, a ... , "These days many people are feeling overwhelmed by stress and fatigue," reports ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the only ... lead a national chief nursing officer recruitment for Jane Phillips Medical ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a ... features the latest and coolest technology products available to consumers. Amanda Forstrom, a technology ... these selfie sticks are great for documenting memories. , Almost every smartphone has an ...
Breaking Medicine News(10 mins):Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... ... the American Heart Association,s PTES campaign to raise funds and awareness for stroke prevention. We ... risk of stroke. Doctors Community Hospital will be onsite at the walk-a-thon providing free health ... Bowie, MD (PRWEB) ...
... A drug whose clinical benefit in treating multiple sclerosis was ... Food and Drug Administration on January 22 and is now ... is the first therapy for multiple sclerosis that can be ... to treat impaired walking, a debilitating symptom of the disease ...
... ... course this past March, and are on their way to becoming the first iPad developers ... ... ), the leader in online and OnDemand iPhone and iPad programming and marketing training, has ...
... Amphora Research Systems ... the revolutionary Apple iPad. , ... (PRWEB) April 5, 2010 -- Amphora Research Systems is delighted to announce the ... ,"Science often happens in places where using a Desktop PC or Laptop is inconvenient, but ...
... MONDAY, April 5 (HealthDay News) -- Researchers report that they,ve ... a finding that offers a possible new avenue toward a ... moment, there,s no way to know whether the research will ... enemy. , Still, the findings do give scientists an idea ...
... ... eco-friendly and affordable Robby Wash high efficiency laundry detergent balls. One Robby Wash hypoallergenic laundry ... saves more than $100 annually. The Robby Wash has been used for years in Europe ... ...
Cached Medicine News:Health News:Bowie/Mitchellville (MD) Alumni Chapter of Kappa Alpha Psi Hosts "Power to End Stroke" Walk-a-thon in Glenn Dale, Maryland 2Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 2Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 3Health News:First iPad App Developers Graduate from Around the Globe: Ready to Show Their New Apps 2Health News:Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad 2Health News:Scientists Find Clues to How the Body Fights Off HIV 2Health News:Robby Wash High Efficiency Laundry Detergent Offers 25% off Coupon – Replaces 75 lbs. of Traditional Laundry Detergent Saving $100 Annually 2Health News:Robby Wash High Efficiency Laundry Detergent Offers 25% off Coupon – Replaces 75 lbs. of Traditional Laundry Detergent Saving $100 Annually 3
... The eNclose Anastomosis ... specifically to obviate the ... of the aorta. The ... the surgeon with a ...
12mm Blades, Maximum Spread 18mm, Spring Action, Wire - Pediatric; in stainless steel...
15mm Open Blades, Thumb Screw Control; in Titanium....
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
Medicine Products: